Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PM28 | ISIN: US3596161097 | Ticker-Symbol:
NASDAQ
30.07.25 | 16:20
6,980 US-Dollar
-8,04 % -0,610
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FULCRUM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
FULCRUM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur FULCRUM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln
DiH.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data1
DiFulcrum Therapeutics, Inc. - 10-Q, Quarterly Report1
DiFulcrum Therapeutics, Inc. - 8-K, Current Report2
DiFulcrum Therapeutics GAAP EPS of -$0.28 beats by $0.011
DiFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 202585- Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious...
► Artikel lesen
DiFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease46- Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% - Evidence...
► Artikel lesen
MoFulcrum Therapeutics-Aktie schießt vor Daten zu Sichelzellkrankheit in die Höhe9
MoFulcrum Therapeutics stock soars ahead of sickle cell trial data3
MoFulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease2
11.07.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)100CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
27.06.Fulcrum Therapeutics, Inc. - 8-K, Current Report2
11.06.Fulcrum Therapeutics auf Goldman Sachs Konferenz: Strategische Updates und Zukunftspläne3
06.06.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)135CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
29.05.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings1
24.05.Leerink raises Fulcrum Therapeutics stock to Outperform3
09.05.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)184CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
01.05.Fulcrum Therapeutics GAAP EPS of -$0.28 beats by $0.013
01.05.Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report2
01.05.Fulcrum Therapeutics, Inc. - 8-K, Current Report1
30.04.Uncovering Potential: Fulcrum Therapeutics' Earnings Preview2
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1